Can-Fite Biopharma Cash Flow - Annual (NYSEMKT:CANF)

Add to My Stocks
$1.32 $0.01 (0.75%) CANF stock closing price Sep 19, 2018 (Closing)

The financial analysis of CANF requires an investor to check the cash flows for Can-Fite Biopharma. While its important to look at the Can-Fite Biopharma debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Can-Fite Biopharma revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Can-Fite Biopharma cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Can-Fite Biopharma had cash and cash equivalents of $9M at the beginning of the year and $3.5M at year end for 2017. Can-Fite Biopharma had an outflow of $-9.54M from operating activities, $4.89M inflow due to financing activities, and $-0.03M outflow due to investing activities for 2017.

View details of Can-Fite Biopharma cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132011
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow------
Net Increase (Decrease) in Assets Liabilities-2.45M-0.45M1.48M-0.96M-0.23M-
Cash From (used in) Discontinued Operations------
Other Adjustments Net-2.12M-1.47M-1.09M-0.06M-2.04M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.03M-0.01M-0.04M-0.01M-0.01M-
Acquisition Disposition of Subsidiaires------
Increase (Decrease) in Investments------
Other Cash Inflow (Outflow) from Investment Activities------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares4.89M-12.38M11.48M13.25M1.32M
Issuance (Repayment) of Debt Securities------
Increase (Decrease) in Bank & Other Borrowings------
Payment of Dividends & Other Cash Distributions------
Other Cash from (used by) Financing Activities-----3.63M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-0.81M-0.11M-0.01M-0.2M--
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year9M17.17M9.24M5.34M1.23M4.9M
Cash & Equivalents at Year End3.5M8.11M16.92M9.28M5.98M4.09M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our Shire financial analysis

While Can-Fite Biopharma stock price history provides the price history of a stock, Can-Fite Biopharma stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Can-Fite Biopharma has cash of $3.5M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Can-Fite Biopharma stock price.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-9.54M for CANF.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-0.03M for CANF in last 2017 report.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Can-Fite Biopharma earned $4.89M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Can-Fite Biopharma Cash Flow